• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Wednesday's Pre-Market Session

    4/24/24 8:06:37 AM ET
    $ADXN
    $BIVI
    $EVO
    $IMMP
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ADXN alert in real time by email

    Gainers

    • Immutep (NASDAQ:IMMP) stock increased by 15.5% to $2.9 during Wednesday's pre-market session. The market value of their outstanding shares is at $344.7 million.
    • Syra Health (NASDAQ:SYRA) stock rose 14.96% to $1.14. The market value of their outstanding shares is at $7.4 million.
    • Sage Therapeutics (NASDAQ:SAGE) shares increased by 13.12% to $14.65. The company's market cap stands at $880.5 million.
    • Recursion Pharmaceuticals (NASDAQ:RXRX) shares moved upwards by 12.72% to $8.68. The market value of their outstanding shares is at $2.0 billion.
    • Viracta Therapeutics (NASDAQ:VIRX) stock moved upwards by 12.05% to $0.95. The company's market cap stands at $37.3 million.
    • BioVie (NASDAQ:BIVI) stock moved upwards by 11.87% to $0.55. The company's market cap stands at $30.2 million.

    Losers

    • Evotec (NASDAQ:EVO) shares declined by 32.2% to $5.19 during Wednesday's pre-market session. The market value of their outstanding shares is at $1.8 billion. The company's, Q4 earnings came out today.
    • Innovative Eyewear (NASDAQ:LUCY) stock decreased by 17.29% to $0.21. The market value of their outstanding shares is at $2.7 million.
    • Ovid Therapeutics (NASDAQ:OVID) stock declined by 15.32% to $2.71. The company's market cap stands at $191.6 million.
    • BiomX (AMEX:PHGE) stock decreased by 14.23% to $0.3. The company's market cap stands at $16.4 million.
    • Kiora Pharmaceuticals (NASDAQ:KPRX) stock decreased by 13.84% to $0.5. The market value of their outstanding shares is at $13.1 million.
    • Addex Therapeutics (NASDAQ:ADXN) stock declined by 13.72% to $16.17. The market value of their outstanding shares is at $17.2 million. The company's, Q4 earnings came out 4 days ago. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $ADXN alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ADXN
    $BIVI
    $EVO
    $IMMP

    CompanyDatePrice TargetRatingAnalyst
    Immutep Limited
    $IMMP
    2/17/2026$6.00Mkt Outperform
    Citizens
    Evotec SE
    $EVO
    2/3/2026Buy
    Berenberg
    Recursion Pharmaceuticals Inc.
    $RXRX
    12/17/2025$11.00Neutral → Overweight
    Analyst
    Ovid Therapeutics Inc.
    $OVID
    12/11/2025$3.00Buy
    Roth Capital
    Ovid Therapeutics Inc.
    $OVID
    11/17/2025Outperform
    Leerink Partners
    Ovid Therapeutics Inc.
    $OVID
    10/9/2025$7.00Outperform
    Oppenheimer
    Ovid Therapeutics Inc.
    $OVID
    8/8/2025$3.00Buy
    B. Riley Securities
    Recursion Pharmaceuticals Inc.
    $RXRX
    7/3/2025$5.00Equal-Weight
    Morgan Stanley
    More analyst ratings

    $ADXN
    $BIVI
    $EVO
    $IMMP
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Innovative Eyewear, Inc. Announces Q4 and Full Year 2025 Earnings Conference Call

    MIAMI, March 10, 2026 /PRNewswire/ -- Innovative Eyewear, Inc. ("Innovative Eyewear" or the "Company") (NASDAQ: LUCY; LUCYW), the developer & manufacturer of smart eyewear under the Lucyd®, Lucyd Armor®, Reebok®, Nautica®, and Eddie Bauer® brands, today announced its upcoming earnings conference call to share the Company's key operational and financial results for the fiscal year ended December 31, 2025. Earnings Call DetailsDate: Tuesday, March 31, 2026Time: 12:00 PM ETParticipant Listening OptionsInterested participants can join the event by using the dial-in numbers, or by cl

    3/10/26 4:30:00 PM ET
    $LUCY
    Ophthalmic Goods
    Health Care

    BiomX Names Michael Oster as Chief Executive Officer, David Rokach Chief Financial Officer to Support Next Phase of Growth

    Seasoned financial leaders join BiomX to support strategic execution and advancement of the companyDOVER, Del. and NESS ZIONA, Israel, March 9, 2026 /PRNewswire/ -- BiomX Inc. (NYSE:PHGE), a clinical-stage company developing natural and engineered phage therapies designed to target and destroy harmful bacteria in chronic diseases, today announced the appointment of Michael Oster as Chief Executive Officer and David Rokach as Chief Financial Officer. Oster brings extensive experience in corporate strategy, mergers and acquisitions, and operational leadership across capital-intensive industries including energy, infrastructure, and industrial sectors. Throughout his career, he has led complex

    3/9/26 9:00:00 AM ET
    $PHGE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    PacBio Announces the Appointment of Chris Gibson to the Board of Directors

    MENLO PARK, Calif., March 05, 2026 (GLOBE NEWSWIRE) -- PacBio (NASDAQ:PACB), a leading provider of high-quality, long-read sequencing technologies, today announced the appointment of Christopher Gibson, Ph.D., to PacBio's Board of Directors. Dr. Gibson is the co-founder and Chairman of the Board of Directors of Recursion (NASDAQ:RXRX), a clinical-stage biotechnology company that has built one of the industry's most advanced AI-driven drug discovery platforms. Under his leadership, Recursion integrated large-scale biological data generation with machine learning to industrialize the discovery process, building a vertically integrated technology stack spanning automation, high-dimensional b

    3/5/26 8:30:00 AM ET
    $PACB
    $RXRX
    Biotechnology: Laboratory Analytical Instruments
    Industrials
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ADXN
    $BIVI
    $EVO
    $IMMP
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Gross Harrison R. bought $1,980 worth of shares (1,500 units at $1.32), increasing direct ownership by 12% to 13,733 units (SEC Form 4)

    4 - Innovative Eyewear Inc (0001808377) (Issuer)

    1/22/26 11:29:05 AM ET
    $LUCY
    Ophthalmic Goods
    Health Care

    Chief Financial Officer Gayle Oswald bought $1,669 worth of shares (1,000 units at $1.67), increasing direct ownership by 54% to 2,865 units (SEC Form 4)

    4 - Innovative Eyewear Inc (0001808377) (Issuer)

    1/15/26 5:00:07 PM ET
    $LUCY
    Ophthalmic Goods
    Health Care

    Chief Executive Officer Gross Harrison R. bought $2,400 worth of shares (1,500 units at $1.60), increasing direct ownership by 14% to 12,233 units (SEC Form 4)

    4 - Innovative Eyewear Inc (0001808377) (Issuer)

    1/12/26 5:00:39 PM ET
    $LUCY
    Ophthalmic Goods
    Health Care

    $ADXN
    $BIVI
    $EVO
    $IMMP
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    August 4, 2023 - La FDA aprueba el primer tratamiento oral para la depresión posparto

    For Immediate Release: August 04, 2023 El día de hoy, la Administración de Alimentos y Medicamentos de los Estados Unidos (FDA, por sus siglas en inglés) aprobó Zurzuvae (zuranolona), el primer medicamento oral indicado para tratar la depresión posparto (DPP) en mujeres adultas. La DPP es un episodio depresivo grave que generalmente ocurre después del parto, pero también puede comenzar durante las últimas etapas

    8/8/23 9:34:19 AM ET
    $SAGE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    August 4, 2023 - FDA Approves First Oral Treatment for Postpartum Depression

    For Immediate Release: August 04, 2023 Today, the U.S. Food and Drug Administration approved Zurzuvae (zuranolone), the first oral medication indicated to treat postpartum depression (PPD) in adults. PPD is a major depressive episode that typically occurs after childbirth but can also begin during the later stages of pregnancy. Until now, treatment for PPD was only available as an IV injection given by a health

    8/4/23 6:50:31 PM ET
    $SAGE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADXN
    $BIVI
    $EVO
    $IMMP
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    $ADXN
    $BIVI
    $EVO
    $IMMP
    SEC Filings

    View All

    $ADXN
    $BIVI
    $EVO
    $IMMP
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Citizens initiated coverage on Immutep with a new price target

    Citizens initiated coverage of Immutep with a rating of Mkt Outperform and set a new price target of $6.00

    2/17/26 8:18:44 AM ET
    $IMMP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Berenberg initiated coverage on Evotec SE

    Berenberg initiated coverage of Evotec SE with a rating of Buy

    2/3/26 6:55:14 AM ET
    $EVO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Recursion Pharmaceuticals upgraded by Analyst with a new price target

    Analyst upgraded Recursion Pharmaceuticals from Neutral to Overweight and set a new price target of $11.00

    12/17/25 8:47:25 AM ET
    $RXRX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 6-K filed by Evotec SE

    6-K - Evotec SE (0001412558) (Filer)

    3/10/26 6:00:54 AM ET
    $EVO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BiomX Inc. filed SEC Form 8-K: Leadership Update

    8-K - BiomX Inc. (0001739174) (Filer)

    3/6/26 8:54:58 AM ET
    $PHGE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    BiomX Inc. filed SEC Form 8-K: Leadership Update, Other Events

    8-K - BiomX Inc. (0001739174) (Filer)

    3/2/26 4:05:47 PM ET
    $PHGE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 4 filed by Kiora Pharmaceuticals Inc.

    4 - KIORA PHARMACEUTICALS INC (0001372514) (Issuer)

    3/10/26 4:36:21 PM ET
    $KPRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Kiora Pharmaceuticals Inc.

    4 - KIORA PHARMACEUTICALS INC (0001372514) (Issuer)

    3/10/26 4:37:12 PM ET
    $KPRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    President and CEO Strem Brian M. was granted 16,733 shares, increasing direct ownership by 36% to 62,598 units (SEC Form 4)

    4 - KIORA PHARMACEUTICALS INC (0001372514) (Issuer)

    3/10/26 4:36:52 PM ET
    $KPRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADXN
    $BIVI
    $EVO
    $IMMP
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Kiora Pharmaceuticals Inc.

    SC 13G/A - KIORA PHARMACEUTICALS INC (0001372514) (Subject)

    11/14/24 7:17:24 PM ET
    $KPRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Sage Therapeutics Inc.

    SC 13G/A - Sage Therapeutics, Inc. (0001597553) (Subject)

    11/14/24 6:14:58 PM ET
    $SAGE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Ovid Therapeutics Inc.

    SC 13G/A - Ovid Therapeutics Inc. (0001636651) (Subject)

    11/14/24 6:01:44 PM ET
    $OVID
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADXN
    $BIVI
    $EVO
    $IMMP
    Leadership Updates

    Live Leadership Updates

    View All

    BiomX Names Michael Oster as Chief Executive Officer, David Rokach Chief Financial Officer to Support Next Phase of Growth

    Seasoned financial leaders join BiomX to support strategic execution and advancement of the companyDOVER, Del. and NESS ZIONA, Israel, March 9, 2026 /PRNewswire/ -- BiomX Inc. (NYSE:PHGE), a clinical-stage company developing natural and engineered phage therapies designed to target and destroy harmful bacteria in chronic diseases, today announced the appointment of Michael Oster as Chief Executive Officer and David Rokach as Chief Financial Officer. Oster brings extensive experience in corporate strategy, mergers and acquisitions, and operational leadership across capital-intensive industries including energy, infrastructure, and industrial sectors. Throughout his career, he has led complex

    3/9/26 9:00:00 AM ET
    $PHGE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    PacBio Announces the Appointment of Chris Gibson to the Board of Directors

    MENLO PARK, Calif., March 05, 2026 (GLOBE NEWSWIRE) -- PacBio (NASDAQ:PACB), a leading provider of high-quality, long-read sequencing technologies, today announced the appointment of Christopher Gibson, Ph.D., to PacBio's Board of Directors. Dr. Gibson is the co-founder and Chairman of the Board of Directors of Recursion (NASDAQ:RXRX), a clinical-stage biotechnology company that has built one of the industry's most advanced AI-driven drug discovery platforms. Under his leadership, Recursion integrated large-scale biological data generation with machine learning to industrialize the discovery process, building a vertically integrated technology stack spanning automation, high-dimensional b

    3/5/26 8:30:00 AM ET
    $PACB
    $RXRX
    Biotechnology: Laboratory Analytical Instruments
    Industrials
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Syra Health Appoints Healthcare Executive and Former U.S. Marine Gregory R. Alexander as Chief Executive Officer to Drive Growth

    Proven C-Suite Leader with Track Record of Scaling Healthcare Organizations Joins Syra Health to Accelerate Market Expansion and Industry Impact CARMEL, Ind., Dec. 18, 2025 /PRNewswire/ -- Syra Health Corp. (OTCQB:SYRA) ("Syra Health" or the "Company"), a healthcare solutions company dedicated to powering better health outcomes through prevention-focused, accessible, and affordable solutions, announced today the appointment of Gregory R. Alexander as Chief Executive Officer, effective January 5, 2026. Alexander's career has been defined by consistently driving growth and excee

    12/18/25 8:55:00 AM ET
    $SYRA
    Diversified Commercial Services
    Consumer Discretionary

    $ADXN
    $BIVI
    $EVO
    $IMMP
    Financials

    Live finance-specific insights

    View All

    Innovative Eyewear, Inc. Announces Q4 and Full Year 2025 Earnings Conference Call

    MIAMI, March 10, 2026 /PRNewswire/ -- Innovative Eyewear, Inc. ("Innovative Eyewear" or the "Company") (NASDAQ: LUCY; LUCYW), the developer & manufacturer of smart eyewear under the Lucyd®, Lucyd Armor®, Reebok®, Nautica®, and Eddie Bauer® brands, today announced its upcoming earnings conference call to share the Company's key operational and financial results for the fiscal year ended December 31, 2025. Earnings Call DetailsDate: Tuesday, March 31, 2026Time: 12:00 PM ETParticipant Listening OptionsInterested participants can join the event by using the dial-in numbers, or by cl

    3/10/26 4:30:00 PM ET
    $LUCY
    Ophthalmic Goods
    Health Care

    Recursion to Report Fourth Quarter and Full Year 2025 Business Updates and Financial Results on February 25

    Salt Lake City, UT, Feb. 18, 2026 (GLOBE NEWSWIRE) -- Recursion (NASDAQ:RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, announced today it will provide business updates and report its fourth quarter and full year 2025 financial results on Wednesday, February 25, 2026, before the open of the financial markets. Recursion will host a (L)earnings Call on February 25, 2026 at 8:00 am ET / 6:00 am MT / 1:00 pm GMT. The company will broadcast the live stream from Recursion's X, LinkedIn, and YouTube accounts. Investors, analysts, and the public will be able to ask questions of the company by submitting questions here: https://forms.gle/TQ4vgUTLKsFm

    2/18/26 8:30:00 AM ET
    $RXRX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    BiomX Announces $3.0 Million Private Placement

    NESS ZIONA, Israel, Dec. 29, 2025 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE:PHGE) ("BiomX" or the "Company"), a clinical-stage company advancing novel natural and engineered phage therapies targeting specific pathogenic bacteria, today announced that it has entered into definitive agreements in connection with a private investment in public equity ("Private Placement") financing for expected gross proceeds of approximately $3.0 million, before deducting placement agent fees and other offering expenses. H.C. Wainwright & Co. acted as the exclusive placement agent for the private placement. About the Private PlacementIn the Private Placement, the Company agreed to issue and sell shares of its Se

    12/29/25 8:00:00 AM ET
    $PHGE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care